Table of Contents Author Guidelines Submit a Manuscript
Journal of Ophthalmology
Volume 2015, Article ID 195737, 4 pages
http://dx.doi.org/10.1155/2015/195737
Research Article

Risk Factors for Refractory Diabetic Macular Oedema after Sub-Tenon’s Capsule Triamcinolone Acetonide Injection

Department of Ophthalmology and Visual Science, Chiba University Graduate School of Medicine, Inohana 1-8-1, Chuo-ku, Chiba Prefecture, Chiba 260-8670, Japan

Received 5 June 2015; Revised 5 September 2015; Accepted 6 September 2015

Academic Editor: Ciro Costagliola

Copyright © 2015 Toshiyuki Oshitari et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. O'Doherty, I. Dooley, and M. Hickey-Dwyer, “Interventions for diabetic macular oedema: a systematic review of the literature,” British Journal of Ophthalmology, vol. 92, no. 12, pp. 1581–1590, 2008. View at Publisher · View at Google Scholar · View at Scopus
  2. J. W. Y. Yau, S. L. Rogers, R. Kawasaki et al., “Global prevalence and major risk factors of diabetic retinopathy,” Diabetes Care, vol. 35, no. 3, pp. 556–564, 2012. View at Publisher · View at Google Scholar · View at Scopus
  3. P. Mitchell, F. Bandello, U. Schmidt-Erfurth et al., “The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema,” Ophthalmology, vol. 118, no. 4, pp. 615–625, 2011. View at Publisher · View at Google Scholar · View at Scopus
  4. M. J. Elman, H. Qin, and L. P. Aiello, “Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results,” Ophthalmology, vol. 119, no. 11, pp. 2312–2318, 2012. View at Publisher · View at Google Scholar
  5. M. B. Sultan, D. Zhou, J. Loftus, T. Dombi, and K. S. Ice, “A phase 2/3, multicenter, randomized, double-masked, 2-year trial of pegaptanib sodium for the treatment of diabetic macular edema,” Ophthalmology, vol. 118, no. 6, pp. 1107–1118, 2011. View at Publisher · View at Google Scholar · View at Scopus
  6. D. V. Do, Q. D. Nguyen, D. Boyer et al., “One-year outcomes of the da VINCI study of VEGF trap-eye in eyes with diabetic macular edema,” Ophthalmology, vol. 119, no. 8, pp. 1658–1665, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. T. S. Kern, “Contributions of inflammatory processes to the development of the early stages of diabetic retinopathy,” Experimental Diabetes Research, vol. 2007, Article ID 95103, 14 pages, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. E. A. Felinski and D. A. Antonetti, “Glucocorticoid regulation of endothelial cell tight junction gene expression: novel treatments for diabetic retinopathy,” Current Eye Research, vol. 30, no. 11, pp. 949–957, 2005. View at Publisher · View at Google Scholar · View at Scopus
  9. M. Nauck, M. Roth, M. Tamm et al., “Induction of vascular endothelial growth factor by platelet-activating factor and platelet-derived growth factor is downregulated by corticosteroids,” American Journal of Respiratory Cell and Molecular Biology, vol. 16, no. 4, pp. 398–406, 1997. View at Publisher · View at Google Scholar · View at Scopus
  10. J. E. Sears and G. Hoppe, “Triamcinolone acetonide destabilizes VEGF mRNA in Müller cells under continuous cobalt stimulation,” Investigative Ophthalmology & Visual Science, vol. 46, no. 11, pp. 4336–4341, 2005. View at Publisher · View at Google Scholar · View at Scopus
  11. N. Ohguro, A. A. Okada, and Y. Tano, “Trans-Tenon's retrobulbar triamcinolone infusion for diffuse diabetic macular edema,” Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 242, no. 5, pp. 444–445, 2004. View at Publisher · View at Google Scholar · View at Scopus
  12. T. C. Ho and W. W. Lai, “Intravitreal cortisone injection for refractory diffuse diabetic macular edema,” Ophthalmologica, vol. 220, no. 5, pp. 349–350, 2006. View at Publisher · View at Google Scholar
  13. T. Sakamoto, T. Hida, Y. Tano et al., “Committee for Triamcinolone Acetonide for Ocular Disease in Japan: survey of triamcinolone acetonide for ocular diseases in Japan,” Nihon Ganka Gakkai Zasshi, vol. 111, no. 12, pp. 936–945, 2007. View at Google Scholar
  14. S. Nonomura, T. Oshitari, M. Arai et al., “The effect of posterior sub-Tenon's capsule triamcinolone acetonide injection to that of pars plana vitrectomy for diabetic macular edema,” Clinical Ophthalmology, vol. 8, pp. 825–830, 2014. View at Publisher · View at Google Scholar · View at Scopus
  15. H.-P. Qi, S. Bi, S.-Q. Wei, H. Cui, and J.-B. Zhao, “Intravitreal versus subtenon triamcinolone acetonide injection for diabetic macular edema: a systematic review and meta-analysis,” Current Eye Research, vol. 37, no. 12, pp. 1136–1147, 2012. View at Publisher · View at Google Scholar · View at Scopus
  16. Y. Takatsuna, S. Yamamoto, Y. Nakamura, T. Tatsumi, M. Arai, and Y. Mitamura, “Long-term therapeutic efficacy of the subthreshold micropulse diode laser photocoagulation for diabetic macular edema,” Japanese Journal of Ophthalmology, vol. 55, no. 4, pp. 365–369, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. M. L. Ribeiro, S. G. Nunes, and J. G. Cunha-Vaz, “Microaneurysm turnover at the macula predicts risk of development of clinically significant macular edema in persons with mild nonproliferative diabetic retinopathy,” Diabetes Care, vol. 36, no. 5, pp. 1254–1259, 2013. View at Publisher · View at Google Scholar · View at Scopus
  18. C. Haritoglou, M. Kernt, A. Neubauer et al., “Microaneurysm formation rate as a predictive marker for progression to clinically significant macular edema in nonproliferative diabetic retinopathy,” Retina, vol. 34, no. 1, pp. 157–164, 2014. View at Publisher · View at Google Scholar · View at Scopus
  19. R. Klein, B. E. K. Klein, S. E. Moss, and K. J. Cruickshanks, “The Wisconsin epidemiologic study of diabetic retinopathy. XV. The long-term incidence of macular edema,” Ophthalmology, vol. 102, no. 1, pp. 7–16, 1995. View at Publisher · View at Google Scholar · View at Scopus
  20. T.-H. Chou, P.-C. Wu, J. Z.-C. Kuo, C.-H. Lai, and C.-N. Kuo, “Relationship of diabetic macular oedema with glycosylated haemoglobin,” Eye, vol. 23, no. 6, pp. 1360–1363, 2009. View at Publisher · View at Google Scholar · View at Scopus
  21. D. S. Fong and R. Contreras, “Glitazone use associated with diabetic macular edema,” American Journal of Ophthalmology, vol. 147, no. 4, pp. 583.e1–586.e1, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. I. Idris, G. Warren, and R. Donnelly, “Association between thiazolidinedione treatment and risk of macular edema among patients with type 2 diabetes,” Archives of Internal Medicine, vol. 172, no. 13, pp. 1005–1011, 2012. View at Publisher · View at Google Scholar · View at Scopus
  23. T. Oshitari, N. Asaumi, M. Watanabe, K. Kumagai, and Y. Mitamura, “Severe macular edema induced by pioglitazone in a patient with diabetic retinopathy: a case study,” Vascular Health and Risk Management, vol. 4, no. 5, pp. 1137–1140, 2008. View at Google Scholar · View at Scopus